How Much Do Vegan Diets Improve the Health of Dogs?
5.9.2024 14:00:00 CEST | ACCESS Newswire | Press release
WINCHESTER, UK / ACCESSWIRE / September 5, 2024 / Pet food consumes at least 9% of all livestock globally, rising to 20% in nations such as the US with high pet ownership. The environmental benefits of vegan pet diets were recently found to be game-changingly large. Most of these relate to dog food. But, can dogs be healthy without consuming meat?
Dogs are biologically omnivores, and many companies now produce vegan dog food using plant, mineral and synthetic ingredients to supply all necessary nutrients. By 2024, 10 scientific studies had demonstrated good health outcomes in dogs fed vegan or vegetarian diets, and the British Veterinary Association had endorsed nutritionally-sound vegan dog diets. Yet no studies had calculated the size of the health benefits that might occur for average dogs, after controlling for age, sex, neutering status, breed size and exercise level - all factors that can affect dog health.
In 2024 veterinary Professor Andrew Knight and two colleagues published the first study to control for all of these factors. After analysing health outcomes for 2,536 dogs, including 336 fed a vegan diet for at least one year, they found decreases in the occurrences of seven general indicators of illness. Dogs fed vegan diets were less likely to need medication, medical diets or unusually high numbers of veterinary visits, were more likely to be assessed as healthy by dog owners and their veterinarians, had lower rates of illness, and fewer cases of health disorders when they were unwell. Reductions ranged from 14% - 51% for average dogs, compared to dogs fed conventional meat-based diets. All of these differences were statistically significant, meaning they almost certainly reflected true differences rather than random variation.
Additionally, the odds of suffering from six specific health disorders fell by 50%-61% compared to dogs fed conventional meat. These included some of the most common health disorders in dogs: problems with body weight, ears, and the musculoskeletal and gastrointestinal system - which can cause conditions such as lameness and diarrhoea.
Among the 22 most common health disorders found in a 2022 study of the same dogs, 11 were most common in dogs fed conventional meat, eight in dogs fed raw meat, and three most common in dogs few vegan diets. 49% of dogs fed conventional meat were unwell, compared to 43% fed raw meat, and 36% fed vegan diets.
Stated Prof. Knight, "Dogs fed vegan diets clearly had the best health outcomes in this very large-scale study, and these results are consistent with prior studies in this field. Nutritionally-sound vegan diets offer extremely large environmental benefits, so this is very good news for dog owners who want to protect the environment whilst also maximising their dogs' health. However, care should always be taken to ensure diets are nutritionally-sound, by checking package labelling and purchasing from reputable pet food companies."
Contact Information
Andrew Knight
Veterinary Professor of Animal Welfare
andrew.knight@murdoch.edu.au
SOURCE: Prof. Andrew Knight
View the original press release on newswire.com.
Representing Animals Foundation

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom